Novo Nordisk A/S Class B (NOVOb)

  • Get an in-depth profile of Novo Nordisk A/S Class B, including a general overview of the company's business and key management, as well as employee data and location and contact information.

Select Exchange

Symbol Exchange Currency
NOVOb Copenhagen DKK Real-time NOVOBc BATS Europe DKK Delayed NVO NYSE USD Real-time 0QIU London DKK Real-time NVON Mexico MXN Delayed NOVCb Frankfurt EUR Delayed NOVCb Xetra EUR Delayed NOVCb Dusseldorf EUR Delayed
1,064.4 -2.6 (-0.24%)
Close DKK Disclaimer

Novo Nordisk A/S Class B Company Profile

Industry
Pharmaceuticals
Sector
Healthcare
Employees
54789
Equity Type
ORD
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
Contact Information
Address
Bagsvaerd,2880 Denmark
Phone
45 44 44 88 88
Fax
-
Web
https://www.novonordisk.com
Top Executives
Name
Age
Since
Title
Sylvie L. Gregoire 62 2015 Independent Director
Mette Bojer Jensen 48 2014 Employee Non-Independent Representative Director
Jeppe Fonager Christiansen 64 2013 Director
Liselotte Hyveled 57 2022 Employee Representative Director
Helge Lund 61 2017 Independent Chairman of the Board
Kasim Kutay 58 2017 Non-Independent Director
Thomas Rantzau 51 2018 Employee Representative Non-Independent Director
Tanja Villumsen 0 2018 Substitute Director
Anders Kaae 0 2018 Substitute Director
Martin W. MacKay 67 2018 Independent Director
Andreas Fibig 61 2018 Independent Director
Laurence M. Debroux 54 2019 Independent Director
Karina Bonde Lenau 0 2018 Substitute Director
Henrik Poulsen 56 2021 Vice Chairman of the Board
Jesper Thorning 0 2018 Substitute Director
Elisabeth Dahl Christensen 0 2022 Employee Representative Director
Christina Law 56 2022 Independent Director

Customize

Clear All
0Selected
Please try another search

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Related Articles